Physician profile
Merrily Fillmore
NPI 1447012695
$858.57
in general payments reported to CMS, 2019-2025
22 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $227 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $122.53 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $122.37 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $91.53 | 2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $61.30 | 2025 | |
| Novo Nordisk INC | $59.13 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.76 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $45.33 | 2025 | Shingrix |
| Collegium Pharmaceutical, INC. | $38.02 | 2025 | Jornay Pm |
| Amgen INC. | $27.33 | 2025 | Repatha, Otezla |
| Astellas Pharma US INC | $24.51 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $21.53 | 2024 | |
| Seqirus USA INC | $20.95 | 2024 | Flucelvax, Fluad |
| Azurity Pharmaceuticals, INC. | $20.43 | 2025 | Horizant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.64 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $18.45 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.10 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.69 | 2024 | Jardiance |
| Qiagen, LLC | $16.06 | 2024 | |
| Abbvie INC. | $15.77 | 2025 | |
| Optumhealth Care Solutions, LLC | $14.36 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Corium, LLC | $14.02 | 2024 | Azstarys |
| Viatris Specialty LLC | $13.76 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merrily Fillmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.